TAVR linked to better outcomes than surgery for women, pooled analysis confirms

Didier Tchétché, MD, an interventional cardiologist and head of the structural heart disease program at Clinique Pasteur in Toulouse, France, and colleagues combined data from the RHEIA and PARTNER 3 trials into a single comparison of TAVR outcomes in female patients.

Didier Tchétché, MD, presents his team's pooled analysis on TAVR outcomes in women at TCT 2024.

New research presented at TCT combined data from the RHEIA and PARTNER 3 trials. “TAVR is a good option, and probably the best one, for an elderly woman," cardiologist Anna Sonia Petronio, MD, explained during the conference.